The goal of this study is to identify the CD63 binding motif of TIMP-1 that could be targeted to inhibit TIMP-1-mediated oncogenic signal transduction while preserving its tumor suppressive MMP-inhibitory functions. The gene discussed is CD63; the disease is neoplasm.